leisure time -WSS

leisure time

author：explore 2025-09-28 19:25:16 - browse：8

Venture capital firm RA Capital is starting a new incubator, setting the stage for the firm to create new startups over the next several years that hone in on synthetic biology, a long-gestating field that insiders say is getting renewed interest.

The Boston-based VC’s incubator is called RASyn, and will be led by Robert Nicol, according to people familiar with the firm’s plans. Nicol spent more than 20 years at the Broad Institute, where he co-founded the MIT-Broad Foundry for Synthetic Biology, as well as HiFiBio Therapeutics and Design Pharmaceuticals.

RA Capital confirmed RASyn’s existence. Senior Managing Director Josh Resnick told STAT it’s part of the firm’s work to rethink how it develops platforms — core technologies or scientific approaches that underpin all of the drugs a biotech develops — but declined to comment further.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： UnitedHealth CEO's Medicaid comments send insurer stocks diving

entertainment

WSS

The thinking behind the controversial eating disorder chatbot Tessa

FDA approves first new drug developed for postpartum depression

Medicare Advantage's lean provider networks lead CMS complaints

Timeline: Key moments in fight for gay rights

A public health expert passes on football's full body collisions for youths

Sea level rise could wash away turtle breeding grounds around the world, researchers say

focus

leisure time

hotspot

Drug repurposing or repositioning? The language matters

Eli Lilly’s Zepbound improved liver scarring in mid

State Dept. review finds Biden bears some blame for Afghanistan failures

Finland to offer bird flu vaccine to select groups of people, a possible global first

Novavax promises a turnaround & Lilly roils the obesity market

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Peter Hotez and the public health issue of online harassment

Living organ donors deserve priority status for transplants

State Dept. review finds Biden bears some blame for Afghanistan failures

Structure Therapeutics oral GLP

focus

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Can medical device makers keep up in the race to treat obesity?

BD to buy Edwards patient monitoring unit for $4.2 billion

Senate panel passes drug pricing bills, but drops one PBM reform

Altering the blood type of lungs raises potential for universal organs for transplants

Sutter Health’s antitrust win overturned by appeals court

hotspot

hotspot

entertainment

hotspot